With scientists racing to identify the nature of human genes, Nils Blythe questions the morality of the venture. The work promises huge benefits for medicine, but should the companies funding it be allowed to reap the rewards of their investment by turning the revolutionary research into commercial property?
Editor Diarmuid Jeffreys NOTE: as The Money Programme is topical, its subject matter may change